Clinical trials with Capivasertib

  • CT-EU-00034272

    Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Testing personalized treatments for advanced prostate cancer

    ProBio is a worldwide study for patients with advanced prostate cancer. It will look at whether new treatments can help patients based on their unique cancer characteristics. Patients are allocated in two groups: one will receive usual care following local guidelines (control group). The other group will be given treatments designed specifically for their type of cancer. These treatments will be chosen based on their cancer’s unique characteristics – what is called ‘biomarker signatures’. Depending on how well they respond to the treatment, patients may be moved to different treatments. Each treatment will be compared to standard care for effectiveness. The researchers will decide if treatments are effective, should continue, or should be stopped. New types and combinations of treatments can be included in the future. The study will use well-established standards to assess cancer improvement. Quality of life and costs of the treatment will also be evaluated. Side effects and responses to treatment at 6 months will also be recorded.

    • Abiraterone
    • Cabazitaxel
    • Radium Chloride Ra-223
    • enzalutamide
    • Apalutamide
    • Niraparib
    • Darolutamide
    • Capivasertib
    • Prednisone
    • Carboplatin
    • Docetaxel
  • Advanced breast cancer treatment study using camizestrant

    This study investigates Camizestrant, alone or combined with other drugs, for advanced breast cancer in women. It’s a Phase 1 trial testing different combinations, including Camizestrant with palbociclib, everolimus, abemaciclib, capivasertib, ribociclib, and anastrozole. The trial aims to assess the safety and tolerability of these treatments in women with endocrine-resistant, ER-positive, HER2-negative breast cancer. It includes multiple parts with dose escalation and expansion to find the most effective and safe dosage.

    • AZD9833 (camizestrant)
    • Capivasertib
    • Abemaciclib
    • Everolimus
    • Ribociclib
    • Palbociclib
    • Anastrozole
  • Testing a new trio of drugs for advanced and metastatic breast cancer

    This study, known as CAPItello-292, is testing a new combination of drugs to see if it can help treat advanced or spreading breast cancer. The drugs include one called capivasertib along with two others known as CDK4/6 inhibitors and another drug called fulvestrant. The study wants to see how well these work together and how safe they are. Firstly, they need to decide on the best dose of these drugs to use together. Then, the main part of the study will compare these drugs with the usual treatment – either of the CDK4/6 inhibitors with fulvestrant — to see which is better. Scientists will check the blood of the patients to see how much of the drugs are present. They also want to see how many people have side effects and how severe these are. Patients’ health will also be monitored, including heart tests, blood tests and checking vital signs. The ultimate goal is to see if this new treatment can slow down the growth of the cancer, or even shrink it. In simpler words, this is a study for people with a type of advanced breast cancer. It’s testing three drugs together — capivasertib, a CDK4/6 inhibitor, and fulvestrant. This study is made up of two parts. The first part is to decide on the right amount of these drugs to give at the same time. Then, they’ll test this against the usual treatment to see if it’s better. They’ll use blood tests to check how much of the drugs are in the body and will carefully watch for any side effects. They’ll also keep a close eye on people’s health overall. The main aim is to see if this new combination can stop the cancer from getting worse. The CAPItello-292 trial is aimed at patients with serious breast cancer that has started to spread. In this research, a new blend of three medicines, capivasertib, a CDK4/6 inhibitor, and fulvestrant, is being evaluated. First, researchers want to figure out the optimal dosing of these drugs when taken together. Then they’ll compare this combination to the standard treatment to see if it provides any additional benefits. They’ll take blood tests to track the amount of medication and continuously monitor for any potential side effects. The end goal is to see if this new drug mixture can slow or even decrease the growth of the cancer.

    • Capivasertib
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • Advanced prostate cancer testing with different drug combinations

    This clinical trial explores a new treatment approach for patients with a specific type of advanced prostate cancer. It compares the effectiveness and safety of capivasertib combined with abiraterone and standard hormone therapy against a placebo combined with abiraterone and standard therapy. The study focuses on patients with hormone-sensitive metastatic prostate cancer characterized by PTEN deficiency, a genetic feature of some tumors. The goal is to find out if capivasertib can better prevent cancer progression and increase survival. This Phase 3 trial involving about 1000 participants is expected to complete by 2027.

    • Abiraterone Acetate
    • Capivasertib